Optimizing the production of suspension cells using the G-Rex M series

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14015-

  Bajgain, Pradip ^a   Mucharla, Roopa ^a   Wilson, John ^b   Welch, Dan ^b   Anurathapan, Usanarat ^a   Liang, Bitao ^c   Lu, Xiaohua ^c   Ripple, Kyle ^d   Centanni, John M ^d   Hall, Christine ^e   Hsu, David ^e   Couture, Larry A ^e   Gupta, Shubhranshu ^a   Gee, Adrian P ^a   Heslop, Helen E ^a   Leen, Ann M ^a   Rooney, Cliona M ^a   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b Wilson Wolf Manufacturing Corporation   (United States)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924797382     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.15     Document Type: Article

References (36)

1. Leen, AM and Heslop, HE (2008). Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 143: 169-179.
2. Rosenberg, SA, Restifo, N P, Yang, JC, Morgan, RA and Dudley, ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
3. Bollard, CM, Gottschalk, S, Leen, AM, Weiss, H, Straathof, KC, Carrum, G et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110: 2838-2845.
4. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166.
5. Comoli, P, Pedrazzoli, P, Maccario, R, Basso, S, Carminati, O, Labirio, M et al. (2005). Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23: 8942-8949.
6. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904.
7. Einsele, H, Roosnek, E, Rufer, N, Sinzger, C, Riegler, S, Löffler, J et al. (2002). Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
8. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
9. Roskrow, MA, Suzuki, N, Gan, Yj, Sixbey, JW, Ng, CY, Kimbrough, S et al. (1998). Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91: 2925-2934.
10. Heslop, HE, Ng, CY, Li, C, Smith, CA, Loftin, SK, Krance, RA et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2: 551-555.
11. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
12. Jin, J, Sabatino, M, Somerville, R, Wilson, JR, Dudley, ME, Stroncek, DF et al. (2012). Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35: 283-292.
13. Leen, AM, Tripic, T and Rooney, CM (2010). Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 10: 337-351.
14. Abbasalizadeh, S and Baharvand, H (2013). Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv 31: 1600-1623.
15. Simaria, AS, Hassan, S, Varadaraju, H, Rowley, J, Warren, K, Vanek, P et al. (2014). Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol Bioeng 111: 69-83.
16. Thirumala, S, Goebel, WS and Woods, EJ (2013). Manufacturing and banking of mesenchymal stem cells. Expert Opin Biol Ther 13: 673-691.
17. Rayment, EA and Williams, DJ (2010). Concise review: mind the gap: challenges in characterizing and quantifying cell-and tissue-based therapies for clinical translation. Stem Cells 28: 996-1004.
18. Ahrlund-Richter, L, De Luca, M, Marshak, DR, Munsie, M, Veiga, A and Rao, M (2009). Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell 4: 20-26.
19. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.
20. Lapteva, N and Vera, JF (2011). Optimization manufacture of virus-and tumor-specific T cells. Stem Cells Int 2011: 434392.
21. Chakraborty, R, Mahendravada, A, Perna, SK, Rooney, CM, Heslop, HE, Vera, JF et al. (2013). Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica 98: 533-537.
22. Lapteva, N, Durett, AG, Sun, J, Rollins, LA, Huye, LL, Fang, J et al. (2012). Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14: 1131-1143.
23. Childs, RW and Berg, M (2013). Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program 2013: 234-246.
24. Bollard, CM, Gottschalk, S, Helen Huls, M, Leen, AM, Gee, AP and Rooney, CM (2011). Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy 13: 518-522.
25. Gerdemann, U, Vera, JF, Rooney, CM and Leen, AM (2011). Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 51, pii: 2736. doi: 10.3791/2736.
26. Sili, U, Leen, AM, Vera, JF, Gee, A P, Huls, H, Heslop, HE et al. (2012). Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy 14: 7-11.
27. Hanley, PJ, Mei, Z, da Graca Cabreira-Hansen, M, Klis, M, Li, W, Zhao, Y et al. (2013). Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy 15: 416-422.
28. +-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31: 2152-2159.
29. Somerville, R P, Devillier, L, Parkhurst, MR, Rosenberg, SA and Dudley, ME (2012). Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. J Transl Med 10: 69.
30. Rodrigues, CA, Fernandes, TG, Diogo, MM, da Silva, CL and Cabral, JM (2011). Stem cell cultivation in bioreactors. Biotechnol Adv 29: 815-829.
31. Somerville, RP and Dudley, ME (2012). Bioreactors get personal. Oncoimmunology 1: 1435-1437.
32. Sadeghi, A, Pauler, L, Annerén, C, Friberg, A, Brandhorst, D, Korsgren, O et al. (2011). Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J Immunol Methods 364: 94-100.
33. Klapper, JA, Thomasian, AA, Smith, DM, Gorgas, GC, Wunderlich, JR, Smith, FO et al. (2009). Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345: 90-99.
34. Malone, CC, Schiltz, PM, Mackintosh, AD, Beutel, LD, Heinemann, FS and Dillman, RO (2001). Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother Radiopharm 16: 381-390.
35. Knazek, RA, Wu, YW, Aebersold, PM and Rosenberg, SA (1990). Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J Immunol Methods 127: 29-37.
36. Anurathapan, U, Chan, RC, Hindi, HF, Mucharla, R, Bajgain, P, Hayes, BC et al. (2014). Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22: 623-633.